Cardia Bioplastics Limited
Myeco Group Ltd, together with its subsidiaries, develops, manufactures, and sells sustainable packaging materials in Oceanic, Asia, the United States, Europe, and Africa. The company supplies biodegradable and compostable resins, packaging products, and cast films to blue-chip companies. It manufactures and distributes polyethylene films, renewable resources resins, and finished products. The co… Read more
Cardia Bioplastics Limited (SCGRF) - Total Assets
Latest total assets as of June 2024: $18.05 Million USD
Based on the latest financial reports, Cardia Bioplastics Limited (SCGRF) holds total assets worth $18.05 Million USD as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cardia Bioplastics Limited - Total Assets Trend (2019–2024)
This chart illustrates how Cardia Bioplastics Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Cardia Bioplastics Limited - Asset Composition Analysis
Current Asset Composition (June 2024)
Cardia Bioplastics Limited's total assets of $18.05 Million consist of 72.0% current assets and 28.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 33.8% |
| Accounts Receivable | $2.63 Million | 14.6% |
| Inventory | $3.17 Million | 17.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Cardia Bioplastics Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cardia Bioplastics Limited's current assets represent 72.0% of total assets in 2024, an increase from 63.5% in 2019.
- Cash Position: Cash and equivalents constituted 33.8% of total assets in 2024, up from 19.7% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 24.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 17.6% of total assets.
Cardia Bioplastics Limited Competitors by Total Assets
Key competitors of Cardia Bioplastics Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
SAMRYOONG Co.Ltd
KQ:014970
|
Korea | ₩96.42 Billion |
|
Zhuhai Zhongfu Enterprise Co Ltd
SHE:000659
|
China | CN¥1.97 Billion |
|
Shin Hwa Silup
KO:001770
|
Korea | ₩84.01 Billion |
|
Huangshan Novel Co Ltd
SHE:002014
|
China | CN¥4.17 Billion |
|
Shenzhen Jinjia Color Printing Group Co Ltd
SHE:002191
|
China | CN¥8.43 Billion |
|
Export Packing
KO:002200
|
Korea | ₩347.30 Billion |
|
Xiamen Hexing Packaging Printing Co Ltd
SHE:002228
|
China | CN¥7.52 Billion |
|
Shenzhen Beauty Star Co Ltd
SHE:002243
|
China | CN¥16.63 Billion |
Cardia Bioplastics Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Cardia Bioplastics Limited generates 0.80x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Cardia Bioplastics Limited is currently not profitable relative to its asset base.
Cardia Bioplastics Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.81 | 4.61 | 4.21 |
| Quick Ratio | 2.88 | 3.51 | 2.61 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $9.58 Million | $ 13.48 Million | $ 15.78 Million |
Cardia Bioplastics Limited - Advanced Valuation Insights
This section examines the relationship between Cardia Bioplastics Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.96 |
| Latest Market Cap to Assets Ratio | 0.77 |
| Asset Growth Rate (YoY) | -35.4% |
| Total Assets | $18.05 Million |
| Market Capitalization | $13.89 Million USD |
Valuation Analysis
Below Book Valuation: The market values Cardia Bioplastics Limited's assets below their book value (0.77 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Cardia Bioplastics Limited's assets decreased by 35.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cardia Bioplastics Limited (2019–2024)
The table below shows the annual total assets of Cardia Bioplastics Limited from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-06-30 | $18.05 Million | -35.44% |
| 2023-06-30 | $27.96 Million | -15.83% |
| 2022-06-30 | $33.22 Million | -1.63% |
| 2021-06-30 | $33.77 Million | +114.37% |
| 2020-06-30 | $15.75 Million | +8.17% |
| 2019-06-30 | $14.56 Million | -- |